Offices of Physicians — U.S. Industry Primer

North American Industry Classification System (NAICS) 2022 code 62111 — a NAICS industry (5-digit) covering two child industries: 621111 (Offices of Physicians, except Mental Health Specialists) and 621112 (Offices of Physicians, Mental Health Specialists).

A Histometrics rollup primer for public-market and private investors. It synthesizes the two child primers plus federal statistics for this 5-digit level; it does not research the topic from scratch.

1. Overview

This is the business of doctors — physicians holding a Doctor of Medicine (MD) or Doctor of Osteopathic Medicine (DO) degree — seeing patients in their own offices rather than in hospitals: primary-care practices, specialist offices, multispecialty groups, and psychiatrists' practices. Taken together it is one of the largest single industries in the U.S. economy by employment, and it is the retail front end of roughly a fifth of all national health spending [6].

The level matters to any investor for the same reason it is hard to own: the cash flows are enormous, recurring, and demographically tailwinded (an aging population buys more physician care every year), yet ownership is scattered across roughly 150,000 firms [2] and, increasingly, across hospitals, insurers, and private-capital platforms — not across tradable pure-play companies. There is no large-cap "offices of physicians" stock.

The single most useful thing this rollup can do is show you that "offices of physicians" is really two very different businesses fused into one code:

• 621111 — everything except mental health is the whale: family medicine, internal medicine, cardiology, orthopedics, dermatology, oncology, surgery, and the rest. It is about 98% of the level's receipts and its economics increasingly revolve around Medicare and value-based-care risk contracts.
• 621112 — psychiatrists' offices is a rounding error by revenue (~2%) but a structurally distinct, faster-growing, supply-constrained specialty with its own regulatory pressure points (controlled-substance telehealth) and its own set of investable platforms.

Editorial view. Demand across the level should stay durable. But returns depend far less on raw patient volume than on physician recruitment and retention, payer contracts, billing performance, local market power, and regulatory discipline — and the shape of the opportunity is completely different in the two children, so they should be underwritten separately.

2. What's inside — the two children and how they differ

The level splits into two child industries that sit next to each other in the code book but behave nothing alike. The contrast is the whole point of reading them together.

Contrast table (federal shares are of the 62111 rollup; see Section 3 for the underlying figures) [1][2]:

How to read the split. 621111 is where the dollars are — and where the consolidation story (hospitals, insurers, private-equity specialty roll-ups) plays out at industrial scale. 621112 is where the scarcity is — a much smaller pool of receipts, but a specialty with rising demand, a hard supply ceiling, and its own distinct platform ecosystem. An investor who buys "physician offices" as one thing will mis-underwrite both: the general-medicine bet is a Medicare-Advantage-medical-cost bet; the psychiatry bet is a recruit-and-retain-scarce-clinicians bet. Note also that HHI here is the standard Herfindahl-Hirschman Index, a concentration score that runs toward 10,000 for a monopoly; both children sit near zero.

Both children exclude a lot of adjacent care. The code specifically walls off dentists, chiropractors, optometrists, podiatrists, and non-physician mental-health practitioners (psychologists, counselors, social workers — NAICS 621330, where most talk therapy lives); outpatient care centers (6214); labs (6215); home health (6216); and — most importantly for sizing — hospitals (622) [3].

3. How big it is (the rollup)

Federal business statistics for NAICS 62111 (our ground-truth file for this level):

Read these carefully. The figures mix reference years (2022 receipts/firms vs. 2023 employment/payroll) and are not a single-period snapshot. Receipts are gross revenue, not profit. The 2.77 million "employees" counts everyone on office payrolls — nurses, medical assistants, front-desk and billing staff — not just physicians. For clinician scale, the U.S. had about 1,032,365 active physicians in 2024, of whom roughly 866,000 were in direct patient care [8]. The two children sum cleanly into these totals: 621111 supplies roughly 98% of receipts and employment and 621112 the rest, which is exactly why the rollup is so lopsided.

Concentration is essentially nil. An HHI of 18 is effectively zero on the 0–10,000 antitrust scale (regulators treat anything below 1,500 as "unconcentrated"), and the four largest firms hold just 6.1% of receipts. On any national reading this is one of the least concentrated large industries in the economy. The real concentration is local, not national (Section 8).

Two undercount caveats — both larger here than in most industries.

1. Employer-only view. County Business Patterns and the Economic Census concentration tables count establishments with paid employees and exclude most government-run operations [1][2]. Solo, cash-only physicians with no staff — a meaningful slice of psychiatry in particular — are "nonemployer" businesses tracked in a separate Census program, and our supplied file has no 62111 nonemployer add-on, so no total for the full self-employed universe is stated here [4]. Where small and individual ownership dominates, treat the establishment and firm counts as a floor.
2. Structural migration. The 62111 line systematically understates total physician-delivered care. As hospitals and health systems buy up practices, the revenue those doctors generate is increasingly classified under hospitals (NAICS 622) or outpatient care centers (NAICS 6214), not here. That is why the level's $640.4 billion of office receipts [2] sits far below the $978 billion the federal health accounts attribute to "physician and clinical services" nationally in 2023 [6]. Likewise, most practicing psychiatrists work for hospitals, academic centers, the VA, community mental-health centers, and correctional systems — activity that lands in other codes, so 621112's ~$10 billion is a small window onto a much larger national spend on psychiatric care.

4. The investable universe (where value concentrates across the children)

There is no clean, pure-play public index for this level. Public exposure is almost always mixed with insurance, pharmacy, hospitals, distribution, technology, or other health services, and most of the real economics sit in private hands. Market-cap and membership figures below are approximate, mid-2026, and several of these are small, volatile stocks.

From the 621111 (general medicine) side — where the dollars are:

• Physician-enablement / value-based-care groups (the closest thing to a direct physician-office bet): Privia Health (PRVA, Nasdaq), agilon health (AGL, NYSE), Astrana Health (ASTH, Nasdaq), and P3 Health Partners (PIII, Nasdaq). These are really wagers on managing Medicare Advantage medical costs, not on office throughput [child 621111].
• Diversified integrators where employed physicians are one segment of a much larger machine: UnitedHealth Group / Optum (UNH) — the country's largest employer/affiliator of physicians, roughly 90,000 doctors, about 10% of the U.S. workforce [19]; CVS Health (CVS, Oak Street Health); Humana (HUM, CenterWell); and Amazon (AMZN, One Medical) [child 621111].
• Specialty MSO / facility exposure inside a broader business: Cardinal Health (CAH, a majority stake in specialty physician platforms such as GI Alliance and Solaris Health) and Surgery Partners (SGRY, surgical facilities and practices) [child 621111].

From the 621112 (psychiatry) side — where the scarcity is:

• Outpatient behavioral platforms: LifeStance Health (LFST, Nasdaq), the largest listed outpatient mental-health platform (psychiatrists, psychologists, therapists), and Talkspace (TALK, Nasdaq), virtual therapy-plus-psychiatry — though Talkspace is primarily an event-driven situation while its acquisition by Universal Health Services (UHS) is pending [child 621112].
• Adjacent facility operators and digital/pharma: UHS and Acadia Healthcare (ACHC) sit in the hospital/residential codes, not offices; Teladoc (TDOC, BetterHelp) and Hims & Hers (HIMS) are digital/consumer; Johnson & Johnson (JNJ) carries psychiatric-drug exposure (e.g., Spravato) [child 621112].

Major private and non-tradable owners (where most of the economics actually sits):

• On the general-medicine side: Kaiser Permanente's Permanente Medical Groups (>25,000 physicians, the largest U.S. medical group) [20]; hospital and academic systems (now over a third of all physicians) [7]; and private-equity-backed specialty roll-ups in dermatology, gastroenterology, ophthalmology, anesthesia, orthopedics, and urology, held through management-services structures [child 621111].
• On the psychiatry side: dedicated telepsychiatry and behavioral platforms — Talkiatry (800+ psychiatrists, ~$452M total funding), KKR's Geode Health, Mindpath Health (Centerbridge / Leonard Green), and the insurance-enablement network Headway [child 621112].

Bottom line. You cannot buy "the level." From the 621111 side you can buy a levered bet on value-based-care execution, or a small slice of employed-physician care inside an insurance giant. From the 621112 side you can buy a small, still-unproven outpatient behavioral platform or adjacent facility operator. In private transactions across both children, remember that the legal owner of the clinical practice, the owner of the management company, and the holder of the economic rights may all be different entities.

5. How the money works

The two children run on different engines, so it pays to hold both models in view.

621111 — fee-for-service plus a capitation overlay. At its core the general-medicine office is a fee-for-service (FFS) billing shop: each patient encounter is coded and billed, and Medicare's Physician Fee Schedule sets the benchmark price via relative value units (RVUs) multiplied by a national dollar conversion factor ($32.35 in 2025) [11]. Revenue is roughly volume × payer mix × contracted rate. The levers that matter are physician productivity (work RVUs per doctor), payer mix (commercial pays best, Medicaid worst), ancillary revenue (in-office labs, imaging, procedures, physician-administered drugs), the overhead ratio (staff, rent, billing typically eat 50%+ of collections), and site of service (hospital-owned practices can add a facility fee on top of the professional fee). Layered on top is the growth model and the public companies' model: value-based care / capitation, in which the group takes a fixed per-member-per-month (PMPM) payment — usually from a Medicare Advantage (MA) plan — and keeps the spread between that payment and the patient's actual medical cost. The key ratio is the medical loss ratio (MLR), the share of premium spent on care; guess the cost wrong and earnings swing hard [child 621111].

621112 — labor, payer mix, and cash-pay. A psychiatry office earns money one visit at a time, is light on equipment, and turns on a few specific levers: reimbursement per visit and payer mix, clinician productivity and schedule-fill (a medication-management visit can run 15–30 minutes, so throughput is high; therapy is lower-throughput), and above all clinician cost, which is the dominant line — the Bureau of Labor Statistics (BLS) reported median psychiatrist pay of $269,940 in May 2025 [13]. Psychiatry is the specialty least likely to take insurance, so a large minority of practices run cash / out-of-network, trading volume for higher, guaranteed per-visit revenue and near-zero billing hassle [child 621112]. A scalable seam is the Collaborative Care Model (CoCM), in which one psychiatrist supervises a care manager and a primary-care doctor to treat a far larger panel indirectly, billed under Medicare CoCM codes [child 621112].

What to watch across both. Same-clinic revenue and visit growth; revenue and visits per full-time clinician; schedule-fill, wait times, and no-show rates (a chronic drag in behavioral care); payer mix, reimbursement rates, collections, denials, and days in accounts receivable; clinician turnover and retention; organic growth versus revenue acquired through deals; and, under risk contracts, attributed patients, PMPM revenue, medical-cost ratio, and shared savings/losses. A practice or platform can post strong reported revenue growth while producing weak cash flow if collections deteriorate, clinicians leave, or acquired locations fail to integrate. Because outside capital enters both children through a management-services organization (MSO) — which owns billing, technology, staffing, and real estate while a physician-owned professional entity holds the clinical license — reported economics can be split across several legal entities.

6. What drives demand

Demand across the level is durable, but the two children lean on different drivers.

Shared, structural:

• Demographics. The population age 65 and older reached 61.2 million in 2024 — 18.0% of all Americans [9], and older patients use far more physician care. Rising Medicare enrollment is the single biggest structural tailwind for general medicine.
• Chronic disease and coverage. Growing prevalence of diabetes, heart disease, and obesity drives visit volume; more insured patients means more paid demand, and coverage losses cut it and worsen payer mix.
• Physician supply. Demand routinely outruns doctor supply. The BLS projects physician-and-surgeon employment to grow about 3% from 2024 to 2034 (~23,600 openings a year) — a labor projection, not a revenue forecast [10]; shortages and burnout cap how much care can be delivered and push up labor costs.
• Site-of-care shift. Care keeps moving from hospitals to lower-cost office, retail, and telehealth settings, expanding what offices do.

621111-specific: Medicare Advantage penetration is what feeds the capitation model, and policy experiments such as the Centers for Medicare & Medicaid Services (CMS) ACO Primary Care Flex model (2025 launch, running through 2029) nudge primary care toward prospective, value-based payment [child 621111].

621112-specific: rising diagnosed prevalence and destigmatization (roughly 23% of U.S. adults — about 59–62 million — had a mental illness in the past year, with nearly half untreated), a hard supply shortage (about 40% of Americans — roughly 137 million — lived in a federally designated Mental Health Professional Shortage Area as of December 2025), telehealth normalization, mental-health parity, and new treatments such as esketamine and transcranial magnetic stimulation [child 621112]. Scarcity, not demand generation, is the binding variable for psychiatry.

7. Regulation

Both children sit inside one of the most heavily regulated revenue models in the economy, and they share the two structural constraints while diverging on a third.

Shared:

• Medicare payment (CMS). The annual Physician Fee Schedule and its conversion factor effectively set the industry's price floor. The schedule has no automatic inflation update and must stay budget-neutral, producing several consecutive years of headline cuts. The Medicare Access and CHIP Reauthorization Act (MACRA) pushes doctors toward the Merit-based Incentive Payment System (MIPS) or Advanced Alternative Payment Models (APMs); beginning in 2026 Medicare splits into two conversion factors — a higher $33.57 for qualifying APM participants and a lower $33.40 for everyone else — plus a one-year statutory +2.5% update, the first meaningful raise in years [11][12].
• Corporate Practice of Medicine (CPOM). Roughly two-thirds of states restrict non-physician corporations from owning practices or employing doctors for clinical work. This is the reason outside capital enters through an MSO that owns the business while a physician-owned professional corporation holds the clinical license (Section 5). A flawed MSO, fee-split, or compensation arrangement can impair a platform's value [14].
• Fraud-and-abuse, privacy, and billing. The Stark Law restricts physician self-referral [15]; the Anti-Kickback Statute bars paying for federal-program referrals [16]; the Health Insurance Portability and Accountability Act (HIPAA) governs patient data [17]; and the No Surprises Act limits out-of-network balance billing [18].

Diverging — the psychiatry-specific lever: because psychiatrists prescribe scheduled drugs (stimulants, benzodiazepines), the Drug Enforcement Administration (DEA) and the Ryan Haight Act govern telehealth prescribing of controlled substances. Pandemic-era flexibilities that waive the in-person-visit requirement have been extended through December 31, 2026, with a permanent "special registration" pathway proposed but not finalized — the single most important open regulatory question for telepsychiatry [child 621112]. Mental-health parity (the Mental Health Parity and Addiction Equity Act, MHPAEA) is a further swing factor for 621112 in-network economics: strengthened 2024 rules are, as of 2025, not being enforced pending litigation, though the underlying statute stands [child 621112].

8. Consolidation

At the national level this is about as unconcentrated as an industry gets — CR4 6.1%, CR50 22.8%, HHI 18 [2] — and both children look the same on that scorecard (CR4 of 6.2% and 5.9% respectively). But the national picture hides intense local consolidation, because patients, physicians, referral relationships, and payer contracts are all geographically specific. The buyers differ by child.

In 621111 (general medicine), three overlapping waves:

1. Hospitals and health systems — the biggest consolidator, now employing 34.5% of physicians [7], often adding facility fees after acquisition.
2. Health insurers — vertical integration led by UnitedHealth/Optum (~90,000 physicians) [19], with CVS (Oak Street), Humana (CenterWell), and Amazon (One Medical) buying primary care to feed Medicare Advantage.
3. Private equity — specialty roll-ups built through MSO structures, where the sponsor owns the management company and captures a fee plus equity upside while doctors retain nominal clinical ownership [14].

In 621112 (psychiatry), the same fragmentation attracts capital, but the vehicles are newer: private-equity roll-ups and de-novo builds (LifeStance, KKR's Geode), venture-funded telepsychiatry networks (Talkiatry, Headway and peers), vertical combinations (the pending UHS–Talkspace deal), and health-system employment — with non-physician substitution (psychiatric nurse practitioners handling routine medication management) easing the shortage while commoditizing routine prescribing [child 621112].

Antitrust attention has focused on the general-medicine side: the Federal Trade Commission's (FTC) 2025 physician-market "6(b)" study documented frequent serial acquisitions and heavy health-system involvement [21], and in early 2025 the agency settled an antitrust case against Welsh Carson over the U.S. Anesthesia Partners roll-up [22]. Federal attention has since cooled, but states are stepping up, enacting merger-notification and private-equity/MSO oversight laws [14]. The net effect across both children: independent practice is shrinking, local markets are concentrating in specific specialties, and clinical decisions increasingly answer to corporate owners.

9. Risks

• Reimbursement pressure. The annual Medicare fee fight, no built-in inflation update, and budget-neutrality cuts squeeze FFS margins [11]; commercial and Medicaid rate pressure and contract terminations compound it. This hits both children.
• The cost squeeze. Labor, rent, and supplies have climbed faster than revenue; clinician compensation is the dominant cost in both — and, in psychiatry, the binding constraint, because a structural shortage means wage inflation and churn [13][child 621111][child 621112].
• Value-based-care / MA downside (mostly 621111). Capitation can blow up when medical costs run above premium, risk adjustment misses, or quality penalties bite. This is the single biggest earnings risk for the public enablers.
• Telehealth policy reversal (mostly 621112). If the DEA reinstates a hard in-person requirement for controlled-substance prescribing, the telepsychiatry model — especially anything involving stimulants — is disrupted [child 621112].
• Payer concentration and revenue-cycle risk. A few plans can control local contracting economics; coding errors, denials, and slow collections turn billed volume into poor cash flow.
• Regulatory and antitrust scrutiny. CPOM enforcement threatens MSO structures; Stark/AKS, fee-splitting, privacy, data-use (the FTC's BetterHelp order is a warning shot), and state private-equity/MSO oversight all affect ownership and deal structures [14][22][child 621112].
• Integration and leverage risk. Debt-funded roll-ups are vulnerable when physicians, staff, or referral sources fail to transfer, or when reimbursement weakens — and roll-up profitability in psychiatry is still being proven rather than established.
• Coverage and affordability. Federal Medicaid tightening reduces covered demand and worsens payer mix; psychiatry's low insurance acceptance limits its addressable population.
• Workforce, clinical, and technology risk. Shortages and burnout cap capacity; a quality or malpractice failure damages cash flow and reputation; telehealth and AI-assisted care could reshape volumes either way.
• Data limitations. Public parents rarely disclose clean NAICS-level revenue, and federal employer statistics exclude the smallest, nonemployer, and government-run practice universe — the undercount is especially large in psychiatry (Section 3).

10. How to invest, and the outlook

Public-market routes — sort by which child you want:

1. General-medicine, value-based execution: PRVA, AGL, ASTH, PIII — small-cap, high-volatility bets on managing Medicare Advantage medical costs, not office throughput.
2. General-medicine, diversified integrators: UNH (Optum), CVS (Oak Street), HUM (CenterWell), AMZN (One Medical) — analyze the segment, not the parent; scale does not eliminate execution risk.
3. General-medicine, specialty/adjacent: CAH (specialty platforms), SGRY (surgical facilities), plus revenue-cycle and health-IT vendors that sell into practices.
4. Psychiatry: LFST (nearest listed outpatient behavioral pure-play), TALK (event-driven pending the UHS deal), adjacent facility operators UHS and ACHC, digital TDOC and HIMS, and pharma JNJ.

Private-market routes (where most of the real economics live):

• Direct practice ownership, buy-ins, and partnership tracks in both children.
• Private-equity funds and MSO platforms rolling up specialties (general medicine) or building telepsychiatry networks (Talkiatry, Geode, Mindpath, Headway).
• Medical-office real estate — directly or via healthcare real estate investment trusts (REITs) that own the buildings practices lease.

Diligence questions for a private buyer (both children). Are collections and cash earnings backed by actual payer remittances? How dependent is the practice on its selling physicians, and will they stay after close? Are payer contracts transferable and economically attractive? Is growth organic or acquisition-driven? Are owner-physician salaries normalized to market? Is the MSO structure legally sound in every state it operates? What are the coding, malpractice, and compliance histories? How much downside sits in capitation or shared-risk contracts (general medicine) or in controlled-substance / telehealth exposure (psychiatry)?

Outlook. The base case is constructive but selective, and it differs by child. For 621111, the 2026 fee schedule's +2.5% statutory bump and new APM-linked conversion factor are the first real Medicare raise in years and modestly ease FFS pressure [12], while the dominant force remains consolidation set against a rising wall of state regulation; the swing factor is Medicare Advantage, where disciplined medical-cost management validates the capitation model and another round of cost-trend misses punishes it. For 621112, demand is unusually durable (rising need, destigmatization, a hard supply ceiling that hands clinicians pricing power), but margins are pressured by the labor shortage and soft reimbursement, and the whole telepsychiatry edifice rests on DEA prescribing rules that remain temporary; treat roll-up profitability as still being proven. Across the level, the structural tailwind — an aging population needing more care — is not in doubt; the open questions are who captures the margin and whether regulators let the current owners keep it. Our supplied federal file for NAICS 62111 contains no revenue-growth forecast, margin benchmark, or complete ownership census, and none is asserted here [1][2].

---

Sources

1. U.S. Census Bureau, County Business Patterns 2023 (NAICS 62111 and children: establishments 218,066; employment 2,771,935; annual payroll ~$290.9B; Q1 payroll ~$68.2B). https://www.census.gov/programs-surveys/cbp.html
2. U.S. Census Bureau, 2022 Economic Census — Concentration / Comparative Statistics (NAICS 62111: receipts $640.4B; firms 149,963; CR4 6.1% / CR8 9.3% / CR20 15% / CR50 22.8%; HHI 18). https://www.census.gov/programs-surveys/economic-census.html
3. U.S. Census Bureau, North American Industry Classification System — 62111 / 621111 / 621112 (scope and cross-references), 2022. https://www.census.gov/naics/?details=62111&input=62111&year=2022
4. U.S. Census Bureau, Nonemployer Statistics (employer-only coverage of CBP/Economic Census; no 62111 nonemployer figure in the supplied file). https://www.census.gov/programs-surveys/nonemployer-statistics.html
5. U.S. Small Business Administration, Table of Small Business Size Standards (621111 = $16M; 621112 = $13.5M average annual receipts), 2023. https://www.sba.gov/document/support-table-size-standards
6. Centers for Medicare & Medicaid Services, National Health Expenditure Fact Sheet (2023 data; physician and clinical services $978B, ~20% of health spending). https://www.cms.gov/data-research/statistics-trends-and-reports/national-health-expenditure-data/nhe-fact-sheet
7. American Medical Association, Physician Practice Benchmark Survey — Physician Practice Arrangements in 2024 (private practice 42.2%, hospital-owned 34.5%, private-equity ~6.5%). https://www.ama-assn.org/about/research/physician-practice-benchmark-survey
8. Association of American Medical Colleges (AAMC), U.S. Physician Workforce Data Dashboard / 2025 Key Findings (~1,032,365 active physicians; ~866,000 in direct patient care). https://www.aamc.org/data-reports/data/2025-key-findings
9. U.S. Census Bureau, Older Adults Outnumber Children in 11 States (65+ population 61.2 million, 18.0% in 2024), 2025. https://www.census.gov/newsroom/press-releases/2025/older-adults-outnumber-children.html
10. U.S. Bureau of Labor Statistics, Occupational Outlook Handbook: Physicians and Surgeons (3% projected growth 2024–2034; ~23,600 annual openings). https://www.bls.gov/ooh/healthcare/physicians-and-surgeons.htm
11. Centers for Medicare & Medicaid Services, Calendar Year 2025 Medicare Physician Fee Schedule Final Rule (conversion factor $32.35), 2024. https://www.cms.gov/newsroom/fact-sheets/calendar-year-cy-2025-medicare-physician-fee-schedule-final-rule
12. Centers for Medicare & Medicaid Services, Calendar Year 2026 Medicare Physician Fee Schedule Final Rule (CMS-1832-F) (dual conversion factors $33.57 / $33.40; +2.5% statutory update), 2025. https://www.cms.gov/newsroom/fact-sheets/calendar-year-cy-2026-medicare-physician-fee-schedule-final-rule-cms-1832-f
13. U.S. Bureau of Labor Statistics, Occupational Employment and Wages — May 2025 (psychiatrists, median $269,940), 2026. https://www.bls.gov/news.release/ocwage.t01.htm
14. American Medical Association, Corporate Practice of Medicine overview, and Milbank Memorial Fund, How MSOs Are Reshaping Physician Practices (CPOM doctrine; MSO structures; state private-equity/MSO oversight trends). https://www.ama-assn.org/practice-management/private-practices/corporate-practice-medicine; https://www.milbank.org/publications/the-corporate-backdoor-to-medicine-how-msos-are-reshaping-physician-practices/
15. Centers for Medicare & Medicaid Services, Physician Self-Referral (Stark Law). https://www.cms.gov/medicare/regulations-guidance/physician-self-referral
16. U.S. Department of Health and Human Services, Office of Inspector General, Fraud & Abuse Laws (Anti-Kickback Statute, False Claims Act). https://oig.hhs.gov/compliance/physician-education/fraud-abuse-laws/
17. U.S. Department of Health and Human Services, HIPAA for Professionals. https://www.hhs.gov/hipaa/for-professionals/covered-entities/index.html
18. Centers for Medicare & Medicaid Services, No Surprises Act — Provider Requirements and Resources. https://www.cms.gov/nosurprises/policies-and-resources/provider-requirements-and-resources
19. STAT News, UnitedHealth/Optum is the largest employer of physicians (~90,000 doctors, ~10% of U.S. workforce), 2023. https://www.statnews.com/2023/11/29/unitedhealth-doctors-workforce/
20. The Permanente Medical Groups / Kaiser Permanente, Our Medical Groups (>25,000 physicians; largest U.S. medical group). https://permanente.org/our-medical-groups/
21. U.S. Federal Trade Commission, First Research Published from Physician 6(b) Study, 2025. https://www.ftc.gov/enforcement/competition-matters/2025/06/first-research-published-physician-6b-study
22. U.S. Federal Trade Commission, FTC Secures Settlement with Private Equity Firm in Antitrust Roll-Up Scheme Case (Welsh Carson / U.S. Anesthesia Partners), 2025. https://www.ftc.gov/news-events/news/press-releases/2025/01/ftc-secures-settlement-private-equity-firm-antitrust-roll-scheme-case
23. Drug Enforcement Administration / McDermott+, DEA Extends Telemedicine Flexibilities for Controlled-Substance Prescribing Through December 31, 2026; proposed special registration, 2025. https://www.dea.gov/documents/2025/dea-extends-telemedicine-flexibilities
24. Substance Abuse and Mental Health Services Administration (SAMHSA), 2023 National Survey on Drug Use and Health (any mental illness prevalence), 2024; and Health Resources and Services Administration (HRSA), State of the Behavioral Health Workforce, 2025 (~62M adults; 40% of population / 137M in a Mental Health Professional Shortage Area as of Dec. 2, 2025). https://www.samhsa.gov/data/; https://bhw.hrsa.gov/data-research
25. LifeStance Health Group, Form 10-K for the Year Ended December 31, 2025 (8,040 clinicians; ~9.0M visits; payer mix), via SEC EDGAR. https://www.sec.gov/Archives/edgar/data/1845257/000119312526071462/lfst-20251231.htm
26. Talkspace, Form 10-K (2025) and Stockholders Vote to Approve Acquisition by UHS ($5.25/share, ~$835M; expected Q3 2026 close), 2026. https://www.sec.gov/Archives/edgar/data/1803901/000119312526105146/talk-20251231.htm; https://talkspace.gcs-web.com/news-releases
27. Corporate disclosures — UnitedHealth (Optum), CVS Health (Oak Street), Humana (CenterWell), Amazon (One Medical), Cardinal Health (specialty platforms), Surgery Partners, Teladoc (BetterHelp), Hims & Hers, Johnson & Johnson (Spravato), Acadia Healthcare, Universal Health Services — via SEC EDGAR. https://www.sec.gov/cgi-bin/browse-edgar
28. Private-platform disclosures — Talkiatry (~$452M total funding; 800+ psychiatrists), KKR/Geode Health, Mindpath Health (Centerbridge / Leonard Green), Headway; and private general-medicine platforms (ChenMed, TeamHealth, U.S. Anesthesia Partners, U.S. Dermatology Partners). https://bhbusiness.com/; https://geode.health/news/; https://www.centerbridge.com/private-equity; https://a16z.com/announcement/investing-in-headway/
29. American Psychiatric Association, Getting Paid in the Collaborative Care Model — Medicare CoCM CPT codes 99492/99493/99494, 2024. https://www.psychiatry.org/psychiatrists/practice/professional-interests/integrated-care/get-paid
30. Medical Group Management Association (MGMA), Provider Compensation and Cost & Revenue data reports (physician-owned vs. hospital-owned collections; operating-cost trends), 2025–2026. https://www.mgma.com/data